Lascco Announces a Licensing Agreement with Abbott

Please login or
register
28.11.2012

Lascco SA announced today the signing of a licensing agreement with global healthcare company Abbott for the commercialization of Pancreatic Stone Protein, a biomarker for sepsis.

Sepstone Diagnostics Sàrl, wholly-owned subsidiary of Lascco SA, has signed a licensing agreement with Abbott (NYSE: ABT) for the commercialization of Pancreatic Stone Protein (PSP), Sepstone’s biomarker for sepsis. Under the terms of this agreement, Abbott will have the right to develop the PSP biomarker for use on its immunochemistry analyzers globally.

Sepsis, a syndrome characterized by an overwhelming systemic response to infection, is among the leading causes of death in intensive care units and accounts for 40% of their total expenditure. Every year, 18 million individuals die from sepsis. In the United States alone, the estimate of cases exceeds 750’000 per year. Despite tremendous research and increasing therapeutic efforts, mortality rates from sepsis remain disappointingly high, ranging between 30% and 50%, mostly attributed to misdiagnosis or delayed diagnosis.
 
Lascco SA is a Swiss-based biotechnology company dedicated to the maturation of early-stage biomedical technologies. The company was founded in 2007.

0Comments

More news about

Lascco SA

Company profiles on startup.ch

Lascco SA

rss